Lifetime cumulative exposure as a threat for neurodegeneration: Need for prevention strategies on a global scale

NeuroToxicology

Volumn 30, Issue 6, 2009, Pages 1144-1148

  Lucchini, Roberto ^a   Zimmerman, Neil ^b  

^a UNIVERSITY OF BRESCIA   (Italy)

^b PURDUE UNIVERSITY   (United States)

Author keywords

Cumulative exposure and effects; Lifetime exposure; Neurotoxicity; Risk assessment

Indexed keywords

BIOLOGICAL MARKER; MANGANESE;

ARTICLE; ATTRIBUTABLE RISK; ENVIRONMENTAL EXPOSURE; HEALTH HAZARD; HUMAN; LIFE CYCLE; LONG TERM EXPOSURE; NERVE DEGENERATION; NEUROTOXICITY; OCCUPATIONAL EXPOSURE; PRIORITY JOURNAL; RISK MANAGEMENT;

BIOLOGICAL MARKERS; ENVIRONMENTAL EXPOSURE; ENVIRONMENTAL HEALTH; HUMANS; NEURODEGENERATIVE DISEASES; NEUROTOXICITY SYNDROMES; NEUROTOXINS; RISK ASSESSMENT; TIME;

EID: 71049161520     PISSN: 0161813X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuro.2009.10.003     Document Type: Article

References (60)

1. Adgate JL, Durkin P, Engel B, Freeman N, Hattis D, Heeringa S, et al. Cumulative and Aggregate Risk Evaluation System (CARES) Model Review. Report of the FIFRA Scientific Advisory Panel. U.S. Environmental Protection Agency, Washington, DC; 2002. http://www.epa.gov/scipoly/sap/index.htm#april [accessed on June 12, 2009].
2. Albert S. Projecting neurologic disease burden. Difficult but critical. Neurology 68 (2007) 322-323
3. Alessio L., Cortesi I., Materzanini P., and Barenghi M. One century of studies on lead poisoning in papers published in La Medicina del Lavoro. Am J Ind Med 38 3 (2000) 361-367
4. ATSDR Toxicological Profile for Manganese Draft for Public Comment U.S. Department of Health and Human Services. Public Health Service. Agency for Toxic Substances and Disease Registry; September 2008. http://www.atsdr.cdc.gov/toxprofiles/tp151.html#bookmark01 [accessed on June 12, 2009].
5. Barlow B.K., Cory-Slechta D.A., Richfield E.K., and Thiruchelvam M. The gestational environment and Parkinson's disease: evidence for neurodevelopmental origins of a neurodegenerative disorder. Reprod Toxicol 23 3 (2007) 457-470
6. Blanc P. How everyday products make people sick (2007), University of California Press, Ltd., London, England
7. Beattie A.D., Moore M.R., and Goldberg A. Tetraethyl-lead poisoning. Lancet 2 7766 (1972) 12-15 Jul 1
8. Budtz-Jørgensen E., Keiding N., Grandjean P., and Weihe P. Estimation of health effects of prenatal methylmercury exposure using structural equation models. Environ Health 1 October (1) (2002) 2
9. Cory-Slechta D.A., Virgolini M.B., Rossi-George A., Thiruchelvam M., Lisek R., and Weston D. Lifetime consequences of combined maternal lead and stress. Basic Clin Pharmacol Toxicol 102 2 (2008) 218-227
10. Cory-Slechta D.A. Studying toxicants as single chemicals: does this strategy adequately identify neurotoxic risk?. Neurotoxicology 26 4 (2005) 491-510
11. Costello S., Cockburn M., Bronstein J., Zhang X., and Ritz B. Parkinson's disease and residential exposure to maneb and paraquat from agricultural applications in the central valley of California. Am J Epidemol 169 8 (2009) 919-926
12. Dorman D.C., McElveen A.M., Marshall M.W., Parkinson C.U., Arden James R., Struve M.F., et al. Maternal-fetal distribution of manganese in the rat following inhalation exposure to manganese sulfate. Neurotoxicology 26 4 (2005) 625-632
13. Dorman D.C., McElveen A.M., Marshall M.W., Parkinson C.U., James R.A., Struve M.F., et al. Tissue manganese concentrations in lactating rats and their offspring following combined in utero and lactation exposure to inhaled manganese sulfate. Toxicol Sci 84 1 (2005) 12-21
14. Dorsey E.R., Constantinescu R., Thompson J.P., Biglan K.M., Holloway R.G., Kieburtz K., et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 68 (2007) 384-386
15. Doull J., and Rozman K.K. Using Haber's law to define the margin of exposure. Toxicology 149 1 (2000) 1-2
16. Egyed M., and Wood G.C. Risk assessment for combustion products of the gasoline additive MMT in Canada. Science Total Environ 189/190 (1996) 11-20
17. Egyed M, Willey G, Walker M, Williams A, Wood GC, Aschner M, et al. Human Health Risk Assessment for Inhaled Manganese. Draft. Water, Air & Climate Change Bureau. Health Canada; March, 2008. http://www.hc-sc.gc.ca/ewh-semt/air/out-ext/_consult/draft_ebauche/index-eng.php [accessed on June 12, 2009].
18. EPA U.S. Environmental Protection Agency. Integrated Risk Information System (IRIS) on manganese (1999), National Center for Environmental Assessment, Office of Research and Development, Washington, DC
19. Feldman R.G. Clinical manifestation of neurotoxic exposure to metals. In: Samules M.A., and Feske S. (Eds). Office practice of neurology (1996), Churchill Livingston, New York 1065-1069
20. Finkelstein M.M., and Jerrett M. A study of the relationships between Parkinson's disease and markers of traffic-derived and environmental manganese air pollution in two Canadian cities. Environ Res 104 (2007) 420-432
21. Frisbie S.H., Ortega R., Maynard D.M., and Sarkar B. The concentrations of arsenic and other toxic elements in Bangladesh's drinking water. Environ Health Perspect 110 (2002) 1147-1153
22. Franco G., and Franco F. Bernardino Ramazzini: the father of occupational medicine. Am J Public Health 91 9 (2001) 1382
23. Gaylor D.W. The use of Haber's law in standard setting and risk assessment. Toxicology 149 1 (2000) 17-19
24. Golub M.S., Hogrefe C.E., Germann S.L., Tran T.T., Beard J.L., Crinella F.M., et al. Neurobehavioral evaluation of rhesus monkey infants fed cow's milk formula, soy formula, or soy formula with added manganese. Neurotoxicol Teratol 27 4 (2005) 615-627
25. Grandjean P., and Landrigan P. Developmental neurotoxicity of industrial chemicals. Lancet 368 9553 (2006) 2167-2178
26. Grandjean P., Bellinger D., Bergman A., Cordier S., Davey-Smith G., Eskenazi B., et al. The Faroes statement: human health effects of developmental exposure to chemicals in our environment. Basic Clin Pharmacol Toxicol 102 2 (2007) 73-75
27. Grieco A. The centenary of the founding of the "Clinica del Lavoro Luigi Devoto" in Milan (1902-2002). The oldest health organization in the world for the study, treatment, and prevention of occupational diseases. Med Lav 94 1 (2003) 26-30 [Italian]
28. Gwiazda R., Campbell C., and Smith D. A noninvasive isotopic approach to estimate the bone lead contribution to blood in children: implications for assessing the efficacy of lead abatement. Environ Health Perspect 113 1 (2005) 104-110
29. Hänninen H. Psychological picture of manifest and latent carbon disulphide poisoning. Br J Ind Med 28 October (4) (1971) 374-381
30. Hernberg S. Lead poisoning in a historical perspective. Am J Ind Med 38 3 (2000) 244-254
31. HUD. Housing and Urban Development, US Department of comprehensive and workable plan for the abatement of lead-based paint in privately owned housing. Report to Congress. Washington; 1995.
32. Kaukiainen A., Vehmas T., Rantala K., Nurminen M., Martikainen R., and Taskinen H. Results of common laboratory tests in solvent-exposed workers. Int Arch Occup Environ Health 77 (2004) 39-46
33. Keifer M.C., and Firestone J. Neurotoxicity of pesticides. J Agromed 12 1 (2007) 17-25
34. Kim E.A., Cheong H.K., Joo K.D., Shin J.H., Lee J.S., Choi S.B., et al. Effect of manganese exposure on the neuroendocrine system in welders. Neurotoxicology 28 2 (2007) 263-269
35. Lotti M., and Moretto A. Organophosphate-induced delayed polyneuropathy. Toxicol Rev 24 1 (2005) 37-49
36. Lucchini R., Placidi D., Toffoletto F., and Alessio L. Neurotoxicity in operating room personnel working with gaseous and nongaseous anesthesia. Int Arch Occup Environ Health 68 3 (1996) 188-192
37. Lucchini R., Apostoli P., Perrone C., Placidi D., Albini E., Migliorati P., et al. Long term exposure to "low levels" of manganese oxides and neurofunctional changes in ferroalloy workers. Neurotoxicology 20 (1999) 287-298
38. Lucchini R., Calza S., Camerino D., Carta P., Decarli A., Parrinello G., et al. Application of a latent variable model for a multicenter study on early effects due to mercury exposure. Neurotoxicology 24 August (4-5) (2003) 605-616
39. Lucchini R., Benedetti L., Albini E., and Alessio L. Neurobehavioral science in hazard identification and risk assessment of neurotoxic agents-what are the needs for further development?. Int Arch Occup Environ Health 78 (2005) 427-437
40. Lucchini R., Albini E., Benedetti L., Borghesi S., Coccaglio R., Malara E., et al. High prevalence of Parkinsonian disorders associated to manganese exposure in the vicinities of ferroalloy industries. Am J Ind Med 50 11 (2007) 788-800
41. Macdonald R.W., Barrie L.A., Bidleman T.F., Diamond M.L., Gregor D.J., Semkin R.G., et al. Contaminants in the Canadian Arctic: 5 years of progress in understanding sources, occurrence and pathways. Sci Total Environ 254 2-3 (2000) 93-234
42. Martin C.J. Manganese neurotoxicity: connecting the dots along the continuum of dysfunction. Neurotoxicology 27 3 (2006) 347-349
43. Montgomery M.P., Kamel F., Saldana T.M., Alavanja M.C., and Sandler D.P. Incident diabetes and pesticide exposure among licensed pesticide applicators: Agricultural Health Study, 1993-2003. Am J Epidemiol 167 10 (2008) 1235-1246
44. Nadeau S.E. Parkinson's disease. J Am Geriatr Soc 45 2 (1997) 233-240
45. Nevin R. Trends in preschool lead exposure, mental retardation, and scholastic achievement: association or causation?. Environ Res 109 3 (2009) 301-310
46. NoMiracle. Novel Methods for Integrated Risk Assessment of CumuLative stressors in Europe. Newletter N. 12. National Environmental Research Institute, University of Aarhus, Denmark; May 2008. ISSN: 1902-6226. http://nomiracle.jrc.it [accessed on June 12, 2009].
47. PHIME (Public health impact of long-term, low-level mixed element exposure in susceptible population strata) Newsletter No. 1. European Union 6th Frame Program, Contract FOOD-CT-2006-016253; 2006. http://www.phime.org [accessed on June 12, 2009].
48. Pirkle J.L., Brody D.J., Gunter E.W., Kramer R.A., Paschal D.C., Flegal K.M., et al. The decline in blood lead levels in the United States. The National Health and Nutrition Examination Surveys (NHANES) JAMA 272 4 (1994) 284-291
49. Racette B.A., Tabbal S.D., Jennings D., Good L., Perlmutter J.S., and Evanoff B. Prevalence of parkinsonism and relationship to exposure in a large sample of Alabama welders. Neurology 64 2 (2005) 230-235
50. Ragas A.M., Brouwer F.P., Büchner F.L., Hendriks H.W., and Huijbregts M.A. Separation of uncertainty and interindividual variability in human exposure modeling. J Expo Sci Environ Epidemiol 19 February (2) (2009) 201-212
51. Rajan P., Kelsey K.T., Schwartz J.D., Bellinger D.C., Weuve J., Sparrow D., et al. Lead burden and psychiatric symptoms and the modifying influence of the delta-aminolevulinic acid dehydratase (ALAD) polymorphism: the VA Normative Aging Study. Am J Epidemiol 166 12 (2007) 1400-1408
52. REACH. Regulation (EC) No. 1907/2006 of the EU Parliament and of the Council of 18 December 2006 concerning the Registration, Evaluation, Authorization and Restriction of Chemical; 2006.
53. RNCOS. Research & Consultancy Solutions. EU Chemical Industry Analysis; November 2007.
54. Rodier J. Manganese poisoning in Moroccan miners. Br J Ind Med 12 1 (1955) 21-35
55. Rohlman D.S., Lucchini R., Anger W.K., Bellinger D.C., and van Thriel C. Neurobehavioral testing in human risk assessment. Neurotoxicology 29 May (3) (2008) 556-567
56. Seppäläinen A.M. Solvents and peripheral neuropathy. Prog Clin Biol Res 220 (1986) 247-253
57. Silbergeld E., and Weaver V.M. Exposure to metals: are we protecting the workers?. Occup Environ Med 64 3 (2007) 141-142
58. Spencer P.S., and Schaumburg H.H. A review of acrylamide neurotoxicity. Part I. Properties, uses and human exposure. Can J Neurol Sci 1 2 (1974) 143-150
59. van Valen E., Wekking E., van der Laan G., Sprangers M., and van Dijk F. The course of chronic solvent induced encephalopathy: a systematic review. Neurotoxicology June (2009) [Epub ahead of print]
60. Zoni S., Albini E., and Lucchini R. Neuropsychological testing for the assessment of manganese neurotoxicity: a review and a proposal. Am J Ind Med 50 11 (2007) 812-830